Delytact oncolytic virus G47∆ approved in Japan for treatment of patients with malignant glioma

Daiichi Sankyo

10 June 2021 - First oncolytic virus ever approved for treatment of malignant glioma or any primary brain cancer.

Daiichi Sankyo today announced that it has received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare for Delytact (teserpaturev/G47∆), an oncolytic virus, for the treatment of patients with malignant glioma.

Delytact previously received Sakigake designation and orphan drug designation from the Ministry of Health, Labour and Welfare for this indication and is now the first oncolytic virus to be approved in any region of the world for treatment of malignant glioma or any type of primary brain cancer.

Read Daiichi Sankyo press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Vaccine , Japan